Overview
US medical device maker's Q1 revenue rose 23% yr/yr, beating analyst expectations
Q1 adjusted EBITDA turned positive and beat analyst expectations
Company repurchased $1.1 mln of stock during the quarter
Outlook
Company raises 2026 revenue guidance to $360 mln-$368 mln from $357 mln-$365 mln
Company maintains 2026 adjusted EBITDA guidance at $49 mln-$51 mln
Company says it will continue to invest and execute with discipline in 2026
Result Drivers
PRODUCT LINE GROWTH - Revenue growth was driven by a 23% increase in lymphedema product sales and a 22% increase in airway clearance product sales
SALES FORCE PRODUCTIVITY - Co said increased productivity from a fully resourced sales organization contributed to revenue growth
GROSS MARGIN EXPANSION - Gross margin rose to 76.5% from 74% in Q1 2025, reflecting operating leverage
Company press release: ID:nGNX2VKj8H
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$75.30 mln
$70.59 mln (5 Analysts)
Q1 EPS
-$0.08
Q1 Net Loss
$1.80 mln
Q1 Adjusted EBITDA
Beat
$3.70 mln
-$56,250 (4 Analysts)
Q1 Operating Income
-$1.50 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Tactile Systems Technology Inc is $39.00, about 70.4% above its May 1 closing price of $22.89
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 29 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)